Johnson & Johnson is distinguished by its steady growth, deep portfolio, and resilience, setting it apart from AI-driven and other pharma peers. The company’s diversified pharma and MedTech assets support robust revenue growth, with 28 platforms generating over $1 billion annually and 13 pharma brands showing double-digit growth. It is expected to deliver reliable 9% annual returns, driven by 8% EPS growth, a 2.4% dividend yield, and disciplined capital allocation. Despite a solid growth outlook and defensive profile, valuation limits a stronger buy rating.
Johnson & Johnson has increased its quarterly dividend by 3.1%, marking 64 consecutive years of dividend growth. The company’s strong cash flow, with nearly double coverage of its dividend payout, and accelerating revenue growth of 9.9% in Q1 2026 su...
The SNPD ETF targets companies with at least 10 years of consecutive dividend growth, blending established Dividend Kings with promising newer payers. Its top holdings include Johnson & Johnson, Procter & Gamble, Coca-Cola, Lowe’s, and PepsiCo, most ...
Johnson & Johnson, McDonald's, and Kinder Morgan stand out as reliable dividend growers heading into late 2026. Johnson & Johnson raised its dividend for the 64th consecutive year, backed by strong revenue and earnings growth driven by oncology produ...
Johnson & Johnson (JNJ) has been upgraded from Hold to Buy due to its consistent performance, stable revenue growth, and defensive qualities. The stock trades at a 20x forward P/E, reflecting a justified premium over peers supported by above-industry...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
